AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11063177
Drug: Droperidol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (2.5 mg)
Trial: 21160196
Drug: Tropisetron (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron (2.5 mg)
Trial: 21160196
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no prophylactic antiemetic treatment)
Trial: 15510018
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori antibody testing by ELISA
Trial: 15510018
Drug: Immunohistochemical analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunohistochemical analysis with H. pylori antibody
Trial: 15510018
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of H. pylori antibodies by ELISA
Trial: 2529048
Drug: Intranasal sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal sufentanil (15 micrograms)
Trial: 2529048
Drug: Intravenous sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sufentanil (15 micrograms)
Trial: 30394507
Drug: Atherectomy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atherectomy treatment in diabetic patients (DM)
Trial: 30394507
Drug: Atherectomy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atherectomy treatment in non-diabetic patients (nDM)
Trial: 25555381
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) administration of Zostavax
Trial: 25555381
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration of Zostavax
Trial: 17112693
Drug: Psidii guajavae
RxNorm normalized name: Psidium guajava extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psidii guajavae folium extract 6 mg/day
Trial: 17112693
Drug: Psidii guajavae
RxNorm normalized name: Psidium guajava extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psidii guajavae folium extract 3 mg/day
Trial: 17112693
Drug: Placebo 3
RxNorm normalized name: placebo 330 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3 mg/day
Trial: 15086613
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment group (P)
Trial: 3067313
Drug: Acetazolamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (250 mg 4 times per day)
Trial: 3067313
Drug: Protriptyline (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protriptyline (20 mg daily)
Trial: 15563538
Drug: Indomethacin (COX-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (COX-1 and COX-2 inhibitor)
Trial: 21777924
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg/d) for 10 days
Trial: 9700950
Drug: Wheat amylase
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat amylase inhibitor (WAI) 4 g
Trial: 360819
Drug: Essential amino
RxNorm normalized name: Essential amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential amino acids (15.7 g daily for 3 months)
Trial: 360819
Drug: Liberal diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal diet (1 g protein/kg body weight)
Trial: 31243158
Drug: Tablet-based avatar
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based avatar version of the bear
Trial: 28260864
Drug: Dexamethasone 5
RxNorm normalized name: dexamethasone 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 5 mg/day or 10 mg/day plus HBO therapy
Trial: 28260864
Drug: HBO therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBO therapy as monotherapy
Trial: 26198966
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 0.5 mg/kg lidocaine and 0.5 mg/kg ketamine, followed by continuous infusion of lidocaine at 0.5 mg·kg(‐1)·h(‐1) till the end of the operation
Trial: 26198966
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion only
Trial: 23260855
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptives (ethinyl E2 and desogestrel) for 9 weeks
Trial: 23260855
Drug: Transdermal patches
RxNorm normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patches (ethinyl E2 and norelgestromin) for 9 weeks
Trial: 21278401
Drug: Metronidazole (MTZ)
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole (MTZ) single-dose 2 g
Trial: 19891046
Drug: Daclizumab induction
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclizumab induction plus low-dose cyclosporine
Trial: 15482753
Drug: Piroxicam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (10 mg orally) before embryo transfer in fresh cycles
Trial: 15482753
Drug: Piroxicam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (10 mg orally) before embryo transfer in frozen-thawed cycles
Trial: 9778615
Drug: Ondansetron (OND)
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron (OND) 8 mg every 6 hours for the first 24 hours (total of 4 doses)
Trial: 9778615
Drug: Ondansetron (OND)
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron (OND) 32 mg as a loading dose before cisplatin, total dose for the first 24 hours
Trial: 8880045
Drug: Draflazine 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Draflazine 3.5 mg
Trial: 2397974
Drug: 10% PVP‐iodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% PVP‐iodine solution and 50% salicylic acid plaster therapy
Trial: 7197979
Drug: amezinium (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amezinium (10 mg i.v.)
Trial: 7197979
Drug: norfenefrine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: norfenefrine (10 mg i.m.)
Trial: 7197979
Drug: dihydroergotamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dihydroergotamine (1 mg i.m.)
Trial: 19021788
Drug: Therapies published
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapies published as case reports (CRs)
Trial: 17556695
Drug: DHA-containing functional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-containing functional food (300 mg DHA/92-kcal bar; average consumption: 5 bars/wk)
Trial: 8822534
Drug: Olanzapine 10
RxNorm normalized name: olanzapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 10 +/- 2.5 mg/day (Olz-M)
Trial: 8822534
Drug: Olanzapine 15
RxNorm normalized name: olanzapine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 15 +/- 2.5 mg/day (Olz-H)
Trial: 8822534
Drug: Haloperidol 15
RxNorm normalized name: haloperidol 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 15 +/- 5 mg/day (Hal)
Trial: 8822534
Drug: Olanzapine 5
RxNorm normalized name: olanzapine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 5 +/- 2.5 mg/day (Olz-L)
Trial: 31206808
Drug: TAC-ER 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC-ER 0.15 mg/kg/day based on adjusted body weight (aBW)
Trial: 31206808
Drug: TAC-ER 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC-ER 0.15 mg/kg/day based on ideal body weight (IBW)
Trial: 29501363
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m2 intravenously weekly for 12 doses) plus carboplatin (area under the curve 6 mg/mL per min, intravenously every 3 weeks, for four cycles) plus veliparib (50 mg orally, twice a day)
Trial: 27922288
Drug: Immediate rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate rehabilitation (physical therapy from day 1 to day 84)
Trial: 27922288
Drug: Traditional rehabilitation
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional rehabilitation (physical therapy from day 29 to day 84)
Trial: 22777673
Drug: Intra-arterial ATP
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial ATP infusions
Trial: 22777673
Drug: KCl infusion
RxNorm normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KCl infusion
Trial: 22777673
Drug: Combined infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined infusion of ouabain and barium chloride (BaCl2)
Trial: 22777673
Drug: Combined ouabain
RxNorm normalized name: ouabain
DrugBank: Ouabain (DB01092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined ouabain plus BaCl2 infusion
Trial: 17568245
Drug: Red yeast
RxNorm normalized name: red yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red yeast rice (600 mg, twice daily for 8 weeks)
Trial: 9973020
Drug: Forced diuresis
RxNorm normalized name: benzalkonium chloride Topical Solution [Clean Force]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forced diuresis with intravenous crystalloid, furosemide, mannitol (if pulmonary capillary wedge pressure <20 mm Hg), and low-dose dopamine (n = 43)
Trial: 9973020
Drug: Intravenous crystalloid
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous crystalloid and matching placebos (n = 55)
Trial: 7072998
Drug: No inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No inhalation agent (Group 1)
Trial: 31225821
Drug: Theta burst
RxNorm normalized name: Coptis teeta root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theta burst repetitive transcranial magnetic stimulation (active treatment)
Trial: 31225821
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control (sham treatment)
Trial: 19251584
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (440 microg twice daily)
Trial: 17237724
Drug: Folate supplementation
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate supplementation in combination with other treatments for IBD
Trial: 15764422
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg and 40 mg)
Trial: 7988776
Drug: 7-hour local
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-hour local hyperglycaemia (5% glucose infusion)
Trial: 2971693
Drug: Topical isotretinoin
RxNorm normalized name: isotretinoin Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical isotretinoin (0.05%)
Trial: 2971693
Drug: Topical tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tretinoin (0.05%)
Trial: 31125055
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg vaccine (month regimen)
Trial: 31125055
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg vaccine (month regimen)
Trial: 28024163
Drug: Psychoeducation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducation group (PEG) intervention program, delivered weekly in a group format over 3 weeks
Trial: 22676906
Drug: Surface neuromuscular
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surface neuromuscular electrical stimulation for 30 minutes, twice a day for 6 weeks in addition to standardized upper limb therapy
Trial: 22676906
Drug: Standardized upper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized upper limb therapy alone
Trial: 7790695
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (500 mg daily for 1 year)
Trial: 7790695
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical appearance tablets for 1 year)
Trial: 2193075
Drug: 5-ASA 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ASA 500 mg suppositories (Asacol) 3 times a day for 1 month
Trial: 154749
Drug: Natural oestrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural oestrogen preparation (piperazine oestrone sulphate)
Trial: 12074225
Drug: Systematic methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic methods of evidence-based medicine
Trial: 7479624
Drug: Social marketing
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social marketing theory (SMT) recruitment materials in Treatment Hall
Trial: 7033426
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (200 mg intramuscularly each week)
Trial: 23522799
Drug: 1.8 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 g/d n‐3 (1.08g eicosapentoaenoic acid + 0.72 g docosahexaenoic acid)
Trial: 23522799
Drug: 40 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g/d walnut
Trial: 23522799
Drug: 2.0 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g/d conjugated linoleic acid (CLA)
Trial: 20360492
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and midazolam (M&M)
Trial: 19212858
Drug: Collagen hydrolysate
RxNorm normalized name: collagen, hydrolyzed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen hydrolysate (CH) 10 g daily for 6 months
Trial: 11864500
Drug: Type I
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type I inactivated vaccine against HFRS
Trial: 8668427
Drug: Complex physical
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex physical tasks (e.g., ball throws)
Trial: 362893
Drug: Trimethoprim-sulfamethoxazole (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (12 mg/kg/day for 10 days)
Trial: 362893
Drug: Sulfamethoxazole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfamethoxazole (50 mg/kg/day for 10 days)
Trial: 21052022
Drug: Beta-blocker or
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker or diuretic monotherapy
Trial: 21052022
Drug: Beta-blocker or
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker or diuretic-based treatment
Trial: 21052022
Drug: Diltiazem-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem-based treatment
Trial: 19319994
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication or interpersonal therapy (RCT participants, n=105)
Trial: 15554569
Drug: Manualized group-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manualized group-based intervention (weekly 90-min sessions over 6 weeks)
Trial: 11133640
Drug: Meperidine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (25 mg IV)
Trial: 11133640
Drug: Clonidine (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.15 mg IV)
Trial: 11133640
Drug: Urapidil (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil (25 mg IV)
Trial: 7881704
Drug: Captopril (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12.5 mg t.i.d.)
Trial: 3144541
Drug: Fleroxacin 600
RxNorm normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 600 mg
Trial: 28606503
Drug: Supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive therapy (SUPPORT)
Trial: 18303486
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg nebicapone
Trial: 18303486
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg nebicapone
Trial: 16782911
Drug: RT/PCV (radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT/PCV (radiotherapy followed by six cycles of standard procarbazine, lomustine, and vincristine chemotherapy)
Trial: 14653888
Drug: Goserelin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (single dose depot preparation)
Trial: 2880811
Drug: Suanzaorentang (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suanzaorentang (250 mg t.i.d.)
Trial: 2880811
Drug: Diazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (2 mg t.i.d.)
Trial: 2880811
Drug: Suanzaorentang (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suanzaorentang (250 mg t.i.d.) and Diazepam (2 mg t.i.d.)
Trial: 20805528
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (100 mg/kg per day)
Trial: 8866037
Drug: One 7
RxNorm normalized name: menaquinone 7
DrugBank: Menaquinone 7 (DB13075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 7 day 17 beta-estradiol transdermal delivery system (TDS)
Trial: 8866037
Drug: Two 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 7 day 17 beta-estradiol transdermal delivery systems (TDSs)
Trial: 1310913
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg daily for 6 months
Trial: 1310913
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg daily for 6 months
Trial: 1310913
Drug: Placebo after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo after 6 months of active treatment
Trial: 30826761
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg daily) in combination with isoniazid (H), rifampicin (R), ethambutol (E), and pyrazinamide (Z) for the first 2 months, followed by HRE for 4 months.
Trial: 30826761
Drug: Standard 6-month
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 6-month anti-TB treatment regimen (HRZE) for the first 2 months, followed by HRE for 4 months.
Trial: 28489273
Drug: Topical minoxidil
RxNorm normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical minoxidil 5% applied twice daily
Trial: 28489273
Drug: Low-level light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level light therapy (LLLT) using the helmet iGrow® device for 25 minutes 3 days weekly
Trial: 28489273
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of topical minoxidil 5% twice daily and LLLT for 25 minutes 3 days weekly for 4 months
Trial: 22988653
Drug: clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clindamycin phosphate 1.2%‐‐benzoyl peroxide (BPO) 2.5% gel
Trial: 22988653
Drug: adapalene 0.1%‐‐BPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adapalene 0.1%‐‐BPO 2.5% gel
Trial: 18005286
Drug: 7% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7% hydrogen peroxide (HP) bleaching solution
Trial: 18005286
Drug: 5% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% hydrogen peroxide (HP) bleaching solution
Trial: 10354808
Drug: Alcohol treatment
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol treatment (mean blood alcohol content = 0.07%)
Trial: 28523482
Drug: Patient-driven titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-driven titration of BIAsp 30
Trial: 25180608
Drug: Investigator-driven titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator-driven titration of BIAsp 30
Trial: 22288732
Drug: Liraglutide (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.2 mg after 6 weeks, 1.8 mg after 12 weeks)
Trial: 19192221
Drug: Varenicline 1
RxNorm normalized name: varenicline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 1 mg bd
Trial: 17428108
Drug: Glycoalkaloid (BEC-5)
RxNorm normalized name: racepinephrine
DrugBank: Racepinephrine (DB11124)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoalkaloid (BEC-5) cream
Trial: 12042428
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (7576 microg or 25,000 IU of retinol palmitate daily)
Trial: 10210264
Drug: NXX-066 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NXX-066 20 mg BID
Trial: 10210264
Drug: NXX-066 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NXX-066 30 mg BID
Trial: 10210264
Drug: NXX-066 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NXX-066 40 mg BID
Trial: 10210264
Drug: NXX-066 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NXX-066 50 mg BID